|
| 产品描述 |
| CHIR-265 is an orally bioavailable small molecule with potential antineoplastic activity.CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms. 5). |
| 化学结构 |
 |
| 化学名称 |
| 1-methyl-5-(2-(4-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine |
| SMILES Code |
| FC(C1=CC=C(NC2=NC3=CC(OC4=CC(C5=NC(C(F)(F)F)=CN5)=NC=C4)=CC=C3N2C)C=C1)(F)F |
| 基本信息 |
产品编号:XM192
产品名称:RAF-265 (CHIR-265)
别名:CHIR 265; CHIR265; CHIR-265; RAF-265; RAF 265; RAF265.
CAS#:405169-16-6
分子式:C24H16F6N6O
精确分子量:518.12898
分子量:518.41
|
| 物化性质 |
外观: 固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3年 -20℃固体储存
2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
